Publications

Export 49 results:
Auteur [ Title(Desc)] Type Année
Filtres: Auteur is Poirier, Judes  [Enlever les filtres]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
E
Benedet AL, Labbe A, Lemay P, Zimmer ER, Pascoal TA, Leuzy A, Mathotaarachchi S, Mohades S, Shin M, Dionne-Laporte A et al..  2015.  Epistasis analysis links immune cascades and cerebral amyloidosis.. J Neuroinflammation. 12:227.
F
Schoemaker D, Poirier J, D Collins L, Gauthier S, Pruessner JC.  2017.  Familiarity deficits in cognitively normal aging individuals with APOE ε4: A follow-up investigation of medial temporal lobe structural correlates.. Alzheimers Dement (Amst). 9:21-24.
H
Konishi K, Joober R, Poirier J, MacDonald K, Chakravarty MM, Patel R, Breitner JCS, Bohbot VD.  2018.  Healthy versus Entorhinal Cortical Atrophy Identification in Asymptomatic APOE4 Carriers at Risk for Alzheimer's Disease.. J Alzheimers Dis. 61(4):1493-1507.
Leduc V, De Beaumont L, Théroux L, Dea D, Aisen P, Petersen RC, Dufour R, Poirier J.  2015.  HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.. Mol Psychiatry. 20(7):867-73.
Meyer P-F, Savard M, Poirier J, Morgan D, Breitner JCS.  2019.  Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology.. Alzheimers Dement. 15(9):1160-1171.
I
Meyer P-F, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan M-É, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner JCS.  2019.  INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.. Neurology. 92(18):e2070-e2080.
Pelleieux S, Picard C, Lamarre-Théroux L, Dea D, Leduc V, Tsantrizos YS, Poirier J.  2018.  Isoprenoids and tau pathology in sporadic Alzheimer's disease.. Neurobiol Aging. 65:132-139.
L
Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER et al..  2019.  Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.. Alzheimers Dement. 15(6):742-753.
Paquette M, Saavedra YGrisel Lun, Poirier J, Théroux L, Dea D, Baass A, Dufour R.  2018.  Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease.. J Geriatr Psychiatry Neurol. 31(2):90-96.
M
Binette APichet, Gonneaud J, Vogel JW, La Joie R, Rosa-Neto P, D Collins L, Poirier J, Breitner JCS, Villeneuve S, Vachon-Presseau E.  2020.  Morphometric network differences in ageing versus Alzheimer's disease dementia.. Brain. 143(2):635-649.
Parent MJ, Zimmer ER, Shin M, Kang MSu, Fonov VS, Mathieu A, Aliaga A, Kostikov A, Carmo SDo, Dea D et al..  2017.  Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.. J Neurosci. 37(50):12263-12271.
De Schutter JW, Park J, Leung CYuen, Gormley P, Lin Y-S, Hu Z, Berghuis AM, Poirier J, Tsantrizos YS.  2014.  Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases.. J Med Chem. 57(13):5764-76.
N
Meyer P-F, Labonte A, Rosa-Neto P, Poirier J, Breitner JCS.  2019.  No apparent effect of naproxen on CSF markers of innate immune activation.. Ann Clin Transl Neurol. 6(6):1127-1133.
O
Lafaille-Magnan M-E, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS.  2017.  Odor identification as a biomarker of preclinical AD in older adults at risk.. Neurology. 89(4):327-335.
P
Poirier J, Miron J., Picard C..  2014.  Pharmacogenomic Approaches to the Treatment of Sporadic Alzheimer Disease using Cholinomimetic Agents. :51-63.
Picard C, Poirier A, Bélanger S, Labonte A, Auld D, Poirier J.  2019.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study.. PLoS One. 14(8):e0220254.
Villeneuve S, Vogel JW, Gonneaud J, Binette APichet, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS et al..  2018.  Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.. JAMA Neurol.
R
Breitner JCS, Poirier J, Etienne PE, Leoutsakos JM.  2016.  Rationale and Structure for a New Center for Studies on Prevention of Alzheimer's Disease (StoP-AD).. J Prev Alzheimers Dis. 3(4):236-242.
Tardif CL, Devenyi GA, Amaral RSC, Pelleieux S, Poirier J, Rosa-Neto P, Breitner JCS, Chakravarty MM.  2018.  Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.. Hum Brain Mapp. 39(2):971-984.
Leduc V, Bourque L, Poirier J, Dufour R.  2016.  Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia.. Pharmacogenet Genomics. 26(1):1-11.
S
Schoemaker D, Poirier J, Escobar S, Gauthier S, Pruessner J.  2016.  Selective familiarity deficits in otherwise cognitively intact aging individuals with genetic risk for Alzheimer's disease.. Alzheimers Dement (Amst). 2:132-9.
T
Miron J, Picard C, Frappier J, Dea D, Théroux L, Poirier J.  2018.  TLR4 Gene Expression and Pro-Inflammatory Cytokines in Alzheimer's Disease and in Response to Hippocampal Deafferentation in Rodents.. J Alzheimers Dis. 63(4):1547-1556.
V
Benedet AL, Yu L, Labbe A, Mathotaarachchi S, Pascoal TA, Shin M, Kang M-S, Gauthier S, Rouleau GA, Poirier J et al..  2018.   variant mitigates Alzheimer disease pathophysiology in vivo and postmortem.. Neurol Genet. 4(1):e216.
Köbe T, Binette APichet, Vogel JW, Meyer P-F, Breitner JCS, Poirier J, Villeneuve S.  2021.  Vascular risk factors are associated with a decline in resting-state functional connectivity in cognitively unimpaired individuals at risk for Alzheimer's disease: Vascular risk factors and functional connectivity changes.. Neuroimage. 231:117832.

Pages